DaVita Inc. (NYSE:DVA) Shares Sold by Mount Lucas Management LP

Mount Lucas Management LP reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 60.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 13,611 shares of the company’s stock after selling 20,522 shares during the quarter. Mount Lucas Management LP’s holdings in DaVita were worth $2,231,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of DaVita by 1.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock valued at $776,000 after purchasing an additional 70 shares during the last quarter. Wedmont Private Capital lifted its stake in DaVita by 4.4% in the third quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after buying an additional 75 shares during the last quarter. Blue Trust Inc. grew its position in shares of DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares during the last quarter. First Trust Direct Indexing L.P. increased its holdings in shares of DaVita by 2.9% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock valued at $500,000 after acquiring an additional 86 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in DaVita by 0.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company’s stock valued at $6,036,000 after purchasing an additional 126 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DVA has been the topic of several research reports. Barclays raised their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial lifted their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. UBS Group lifted their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, TD Cowen upped their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $161.80.

Insider Buying and Selling at DaVita

In related news, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the sale, the chief financial officer now owns 111,481 shares in the company, valued at $17,286,243.86. This represents a 36.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 156,086 shares of company stock valued at $24,807,161. Corporate insiders own 2.00% of the company’s stock.

DaVita Trading Up 3.9 %

Shares of DVA stock opened at $160.33 on Friday. The business’s fifty day moving average price is $157.78 and its 200 day moving average price is $147.56. The firm has a market capitalization of $13.15 billion, a PE ratio of 17.30, a P/E/G ratio of 0.90 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a 1-year low of $92.68 and a 1-year high of $168.50.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same period last year, the company earned $2.85 earnings per share. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, sell-side analysts forecast that DaVita Inc. will post 9.71 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.